Due to the strong promise of gene therapy, there is an increased demand of AAV/LV in clinical trials. Supported by optimized cell lines, such as suspension HEK293 or Sf9, an emerging trend is to scale the bioreactor volume, in some cases above thousands of liters. At large scale, fluid handling and cell disruption become serious operational hurdles. To be used for cell lysis in large-scale production, an ideal lysis reagent would need low viscosity and deliver consistent results in standard process conditions. Effective legacy detergents like Triton™ X-100 and Polysorbate 20, are now either restricted under REACH due to environmental concerns, or often lacks consistent performance across process conditions, such as cell density and temperature, making it difficult to identify a scalable reagent for large-scale cell lysis in AAV harvest. What’s needed is a new solution, one that is scalable, effective, and aligns with today’s growing demands for sustainable, regulatory-ready bioprocessing.

In this webinar, key data for J.T.Baker^® Cell Lysis Solution will demonstrate how the product’s properties are suited for setting a new benchmark for upstream AAV processing. The presenter will also uncover how J.T.Baker^® Cell Lysis Solution could optimize the AAV harvest, delivering added value through seamless compatibility with DNA digesting enzymes and viral inactivation capabilities. Unlock smarter, more efficient scaling for your next gene therapy run.

Key Takeaways:

• Learn about an ideal cell lysis reagent for large-scale production and why it requires ease-of-use properties such as low viscosity and consistent performance across conditions.
• Analyze regulatory compliance for detergent-based products and Triton X-100 alternatives.
• Understand complementary features such as compatibility with J.T.Baker^® Endonuclease and viral inactivation for optimized AAV harvest process.